Back
Crinetics Pharmaceuticals Inc (CRNX)
PharmaceuticalsCRNX · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$84.95
+0.13%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$-4.95
ROE
-39.2%
Gross margin
0.0%
Debt/Equity
3.74x
Revenue growth
2873.4%
P/B ratio
Beta
Forward P/E
Crinetics Pharmaceuticals Inc — company intelligence
Earnings surprises
Q2 2026$-1.14 vs $-1.23 est+7.6%
Q1 2026$-1.23 vs $-1.26 est+2.5%
Q4 2025$-1.29 vs $-1.39 est+7.5%
Q3 2025$-1.38 vs $-1.28 est-7.8%
Analyst consensus · 20 analysts
6 Buy14 Hold0 Sell
Updated Oct 10, 2026
Insider activity · 90 days
1 buy87 sellsnet -5,046,632 shares
WIERENGA WENDELLSell 116,146 · Sep 1, 2026
Bedrosian Camille LSell 9,730 · Sep 1, 2026
Bedrosian Camille LSell 10,350 · Sep 1, 2026
Recent SEC filings
4 — Insider transaction reportSep 1, 2026
4 — Insider transaction reportSep 1, 2026
4 — Insider transaction reportSep 1, 2026
Latest news
Top 3 Health Care Stocks That May Implode In August — Benzinga · Aug 12, 2026
Crinetics Pharmaceuticals (CRNX) On Vertex Deal Optimism And Results Looks Nearly Fully Valued — Yahoo · Aug 4, 2026
Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says — Yahoo · Aug 4, 2026
Vertex Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary — Yahoo · Aug 4, 2026
Crinetics Pharmaceuticals (CRNX) Stock Looks Pricey As Buyout News Lands — Yahoo · Aug 4, 2026
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.